A Human ICAM-1 Antibody Isolated by a Function-First Approach Has Potent Macrophage-Dependent Antimyeloma Activity In Vivo-Reference-Cited by-同舟云学术

A Human ICAM-1 Antibody Isolated by a Function-First Approach Has Potent Macrophage-Dependent Antimyeloma Activity In Vivo

Published:2013-04 Issue:4 Volume:23 Page:502-515
ISSN:1535-6108
Container-title:Cancer Cell
language:en
Short-container-title:Cancer Cell

Author:

Veitonmäki Niina,Hansson Markus,Zhan Fenghuang,Sundberg Annika,Löfstedt Tobias,Ljungars Anne,Li Zhan-Chun,Martinsson-Niskanen Titti,Zeng Ming,Yang Ye,Danielsson Lena,Kovacek Mathilda,Lundqvist Andrea,Mårtensson Linda,Teige Ingrid,Tricot Guido,Frendéus Björn

Publisher

Elsevier BV

Subject

Cancer Research,Cell Biology,Oncology

Reference43 articles.

1. Gene expression of angiogenic factors correlates with metastatic potential of prostate cancer cells;Aalinkeel;Cancer Res.,2004

2. The future of anti-CD20 monoclonal antibodies: are we making progress?;Alduaij;Blood,2011

3. Strategies and challenges for the next generation of therapeutic antibodies;Beck;Nat. Rev. Immunol.,2010

4. Type II (tositumomab) anti-CD20 monoclonal antibody out performs type I (rituximab-like) reagents in B-cell depletion regardless of complement activation;Beers;Blood,2008

5. Impact of FcgammaRIIa-FcgammaRIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan;Bibeau;J. Clin. Oncol.,2009

Cited by 66 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Phage display for discovery of anticancer antibodies;New Biotechnology;2024-11

2. Therapeutic Targeting Tongue Squamous Cell Carcinoma via ICAM1 Antibody‐Drug Conjugates in Preclinical Models;Advanced Therapeutics;2024-07

3. A review of biological targets and therapeutic approaches in the management of triple-negative breast cancer;Journal of Advanced Research;2023-12

4. Resolving therapy resistance mechanisms in multiple myeloma by multiomics subclone analysis;Blood;2023-11-09

5. CD38 x ICAM-1 Bispecific Antibody Is a Novel Approach for Treating Multiple Myeloma and Lymphoma;Molecular Cancer Therapeutics;2023-10-10